Ischaemic stroke
RecruitingA Study of TGD001 in Patients with Acute Ischemic Stroke to Test Safety and Effectiveness
A Study of TGD001 in Patients with Acute Ischemic Stroke to Test Safety and Effectiveness
- Disease:Ischaemic stroke
- Substances:Urokinase, catalytic domain, fused with a single-chain antibody against VON willebrand factor
Poland- Participants:18–64 years · 65+ years
- Substances:Urokinase, catalytic domain, fused with a single-chain antibody against VON willebrand factor
- Sponsor:TargED Biopharmaceuticals B.V.











